The trial has an "adaptive" design and could quickly move from dozens of patients to eventually include thousands, Chief Scientific Officer George Yancopoulos told Reuters.
The dual antibody, called REGN-COV2, is being compared to a placebo treatment in hospitalized COVID-19 patients, and in COVID-19 patients who have symptoms but are not sick enough to be hospitalized. Antibodies are proteins made by the body's immune system that recognize, bind and neutralize an invading virus.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: